These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25143713)

  • 1. Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.
    Miguelino MG; Powell JS
    Patient Prefer Adherence; 2014; 8():1073-83. PubMed ID: 25143713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasting power of new clotting proteins.
    Powell JS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):355-63. PubMed ID: 25696879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eftrenonacog Alfa: A Review in Haemophilia B.
    Lamb YN; Hoy SM
    Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
    Ducore JM; Miguelino MG; Powell JS
    Expert Rev Hematol; 2014 Oct; 7(5):559-71. PubMed ID: 25142322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM
    Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer-acting clotting factor concentrates for hemophilia.
    Powell JS
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S167-75. PubMed ID: 26149018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
    Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B:
    Astermark J; Hermans C; Ezzalfani M; Sidhom A; Barbier S; Kragh N; Falk A; Eriksson D
    Ther Adv Hematol; 2023; 14():20406207231170701. PubMed ID: 37283819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the management of moderate-to-severe hemophilia B.
    Nazeef M; Sheehan JP
    J Blood Med; 2016; 7():27-38. PubMed ID: 27099538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management.
    Benitez-Hidalgo O; Suito Alcántara M; Martinez Garcia MF; Campoy D; Olivera P; Gironella Mesa M; Juarez-Gimenez JC
    Clin Case Rep; 2024 Feb; 12(2):e8121. PubMed ID: 38333660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report.
    Bohn JP; Fiala A; Bachmann S; Irsara C; Wolf D; Feistritzer C
    Ther Adv Hematol; 2022; 13():20406207221104595. PubMed ID: 35923771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.